QI
ARRY

Quotient Investors’s Array Biopharma Inc ARRY Stock Holding History

Quotient Investors’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-10,600
Closed -$76K – 274
2015
Q2 		$76K Buy
+10,600
New +$78.2K 0.01% 245

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Quotient Investors's ARRY Position: Q3 2015 in Review

Quotient Investors sold out of Array Biopharma Inc (ARRY) in Q3 2015, closing a stake of 10,600 shares — an estimated $76K sold.

Quotient Investors first reported a position in ARRY in Q2 2015 and held it in 1 quarter. The position peaked at $76K in Q2 2015. 157 funds tracked by Wall St. Rank hold ARRY as of Q3 2015.

  • Quotient Investors reported no remaining Array Biopharma Inc position as of Q3 2015 after selling out during the quarter.
  • Quotient Investors sold 10,600 Array Biopharma Inc shares in Q3 2015, an estimated $76K.
  • Quotient Investors first reported a position in Array Biopharma Inc in Q2 2015 and held it in 1 quarter.
  • Quotient Investors's Array Biopharma Inc position peaked at $76K in Q2 2015.
  • 157 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2015.

Based on Quotient Investors's 13F filing for Q3 2015, filed 21 Oct 2015.